Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data - Top-Institutions - MDSpire

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • By

  • Igor Snast

  • Yuliya Valdman-Grinshpoun

  • Naji Bathish

  • Hagit Matz

  • Yuri Shclar

  • Sari Murad

  • Tali Czarnowicki

  • Eran Shavit

  • Liuqing Yang

  • Sandra Goss

  • Inbal Piller Maor

  • Assaf Halperin

  • Shiran Naftalberg Blonder

  • Raanan Cohen

  • Alex Bleterman

  • Moran Barak

  • Lev Pavlovsky

  • March 31, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Digital Health

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Medicine

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #5

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Digital Health Research

Original Source(s)

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • by Igor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, Hagit Matz, Yuri Shclar, Sari Murad, Tali Czarnowicki, Eran Shavit, Liuqing Yang, Sandra Goss, Inbal Piller Maor, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Lev Pavlovsky

  • March 31, 2026

Related Content

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial